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Abstract
Background: Erectile dysfunction (ED) is a predictor or marker of coronary artery disease in patients 
at high risk of cardiovascular diseases. The aim of this study was to investigate the prevalence of ED 
in patients with acute myocardial infarction (AMI) and after 2 years of follow-up, and to determine the 
association between ED and the concentrations of the markers of inflammation, endothelial dysfunction 
and oxidative stress which were measured on the third day after hospital admission.
Methods: The study included 80 patients aged 62.25 ± 10.47 years. The primary endpoints of interest 
were re-hospitalization due to cardiovascular causes and death during the 2 year period after hospital-
ization. The Sexual Health Inventory for Men (SHIM) was assessed at the point of hospital discharge 
and 24 months thereafter.
Results: 40.1% of patients had some degree of ED. The percentage of patients without ED increased 
(13.2%), while the percentage of patients with severe ED significantly decreased (14.7%) after 2 years. 
Patients with ED had significantly higher B-type natriuretic peptide (BNP) levels and decreased levels 
of nitric-oxide. During the 2 years of follow-up, 9 patients died (6.5% without ED, 68.6% with ED) 
(c2 = 7.19, p = 0.015). During the same time period, 22 (27.5%) patients were re-hospitalized due to 
cardiovascular causes, of whom 59.1% had ED at hospital admission (p < 0.05).
Conclusions: Low levels of nitric-oxide were the best predictors of ED during AMI and after 2 years. 
ED predicted the worst outcomes of AMI: death and re-hospitalization. Lifestyle changes and nitric-
-oxide donors could assist in the treatment of ED and in the improvement of long-term prognosis for 
AMI. (Cardiol J 2017; 24, 4: 393–402)
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Introduction
Erectile dysfunction (ED) is defined as the 
persistent inability to achieve and maintain an 
erection sufficient to provide adequate sexual activ-
ity. ED is a common and important cause of poor 
quality of life and psychosocial morbidity in men. 
The Massachusetts male aging study was the first 
population study to address this issue, in which it 
was shown that the prevalence of ED was 52% in 
men aged 40–70 years [1].
The causes of ED can be predominantly or-
ganic, psychogenic or a combination of both. The 
most common organic causes are vascular, hormo-
nal and neurogenic.
Penile erection is largely a vascular process 
and the penile endothelium and smooth muscle 
cells are very sensitive to structural and functional 
changes. Vasculogenic ED is caused by the impair-
ment of the endothelium-dependent relaxation of 
the smooth muscles (functional vascular ED, the 
initial stage), by the occlusion of cavernous arte-
393www.cardiologyjournal.org
CLINICAL CARDIOLOGY
Cardiology Journal 
2017, Vol. 24, No. 4, 393–402
DOI: 10.5603/CJ.a2017.0006 
Copyright © 2017 Via Medica
ISSN 1897–5593ORIGINAL ARTICLE
ries due to atherosclerosis (structural vascular 
ED, later phase) or by a combination of both of 
these factors. New studies support the complex 
interdependence between endothelial dysfunc-
tion, inflammation and the subclinical deficiency 
of androgen hormones in ED etiology [2].
Erectile dysfunction is a predictor or marker of 
coronary artery disease (CAD) in patients at high 
risk of cardiovascular diseases (CVD). Subanalysis 
of the ONTARGET and TRANSCEND studies 
have shown that men with ED are at higher risk of 
cardiovascular (CV) mortality, myocardial infarction 
(MI), and all-cause mortality than men without ED 
[2, 3]. In a meta-analysis, Guo et al. [4] showed that 
men with ED have a 47% increased relative risk 
of CV events and a 41% increased relative risk of 
CVD compared to healthy people. Dong et al. [5] 
found in their meta-analysis that ED is associated 
with an increased risk of 48% for CVD, 46% for 
coronary heart disease (CHD), 35% for a stroke, 
and 19% for all-cause mortality. Vlachopoulos et al. 
[6] reported in a meta-analysis that ED is indepen-
dently associated with a 44% increase in the risk 
of total CV events, a 62% increase for MI, a 39% 
increase for cerebrovascular events, and 25% for 
all-cause mortality [6]. 
The precise mechanism which could explain 
this connection has not yet been elucidated. There 
are a number of theories without extensive ex-
perimental validation. The most popular hypoth-
esis explaining this association is the “artery size 
hypothesis” according to which the penile arteries 
are affected by atherosclerosis at the same time and 
in the same manner as coronary arteries, but since 
they have a smaller diameter, they show symptoms 
before heart vessels do. Therefore, ED precedes 
CHD and could be its early marker. Also, some 
authors have hypothesized that systolic hyperten-
sion and arterial stiffness lead to the degeneration 
of penile arterial walls in older age, and that those 
mechanisms are responsible for ED development. 
In addition, some studies associate mental depres-
sion with CHD and ED [4–6].
Newer studies recognize ED as a marker of 
a prothrombotic state. Therefore, the co-existence 
of ED and atrial fibrillation (AF) could be regarded 
as a consequence of a micro-thrombosis in AF pa-
tients, which could affect penile arteries and lead 
to ED, besides the other mechanisms involved in 
ED development such as endothelial dysfunction, 
inflammation and oxidative stress [7, 8].  
Nitric-oxide (NO) is considered to be the link 
between ED and CVD. The initial damage to the 
endothelium-dependent vasodilatation may lead 
to a number of structural abnormalities in the 
vasculature and to atherosclerosis of the penile 
arteries, which reduces blood flow. Therefore, the 
penile vascular bed can be a sensitive indicator of 
systemic vascular disease. Subclinical inflammation 
affects the endothelial function, which may lead to 
a prothrombotic state. Several studies have shown 
that the development and severity of ED are associ-
ated with the increased expression of inflammatory 
markers. Inflammation may be responsible for the 
increased risk of coronary events in patients with 
ED even in the absence of obstructive lesions in 
the coronary blood vessels. The proinflammatory 
and prothrombotic state in ED causes a predispo-
sition to the rupture of unstable, not necessarily 
obstructive, coronary plaques and consequently to 
the development of acute coronary events [2, 3].
Data suggest that endothelin-1 (ET-1) is 
a strong vasoconstrictor and could increase the 
oxidative stress in the penile arteries leading to 
endothelial dysfunction and to atherosclerosis [9].
The primary aim of this study was to deter-
mine the prevalence of ED in patients with acute 
MI (AMI) as measured on the third day after 
hospital admission and after 2 years of follow-up, 
as well as to test the association between ED and 
the concentrations of the markers of endothelial 
dysfunction, oxidative stress and inflammation. 
In previous studies, the markers of endothelial 
dysfunction (NO, ET-1 and albuminuria) showed 
the best predictive role for CV morbidity and 
mortality 72 h after AMI [10–12]. The second aim 
was to investigate the impact of therapy after AMI 
(nitric donors in particular and lifestyle changes) 
on erectile function.
Methods
A prospective study included 80 patients with 
AMI aged from 40 to 84 years (62.25 ± 10.47). 
Diagnosis and treatment of AMI was made accord-
ing to the guidelines of the European Society of 
Cardiology [13]. All patients were Caucasian, had 
a minimum of elementary school education, had 
a stable financial income and were married. The esti - 
mated sample size for the 5% expected increase in 
the number of patients with ED, after 2 years, for 
a power of 0.8 was 87 participants. Patients excluded 
from the study were those with diabetes mel-
litus, chronic inflammatory diseases (e.g. chronic 
obstructive pulmonary disease, inflammatory 
bowel disease, connective tissue disorders, and 
rheumatoid arthritis), coagulopathy, and chronic 
renal and respiratory failure in which the markers 
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of inflammation, oxidative stress and endothelial 
dysfunction increase as part of the underlying 
disease. Also, patients treated for urogenital disor-
ders were excluded. All participants gave written 
informed consent, and the study was conducted 
according to the Helsinki Declaration and local 
Ethics Committee. The participants were observed 
for 24 months and the endpoints of interest were 
re-hospitalization due to CV causes and death. Data 
were collected during scheduled clinical controls 
every 6 months. For those who died during the 
follow-up period, data were obtained from the fam-
ily physician and death certificates. Blood samples 
for routine analysis were obtained on admission (in-
cluding biochemical analysis, complete blood count, 
high-sensitivity troponin I (hsTnI) and B-type 
natriuretic peptide [BNP]). Concentrations of BNP, 
high-sensitivity C-reactive protein (hsCRP), and 
hsTnI were analyzed according to the description 
of the manufacturer (BNP [ARCHITECT ASSAY, 
Abbott, USA], hsCRP [BECKMAN COULTER, 
USA], hsTnI [ARCHITECT STAT High sensitive 
Troponin-I assay, Abbott Diagnostics, USA]).
The ELISA method, produced by a commercial 
test company R&D Systems, R&D Company, Min-
neapolis, USA, was used to determine the ET-1 
level. Venous blood was collected in a potassium 
EDTA-coated vacutainer for the indirect measure-
ment of NO by determining the concentration of 
nitrite/nitrate (NO2-/NO3-) in plasma. The plasma 
samples were stored at –20°C. The concentra-
tion of nitrate and nitrite was measured using 
a modified cadmium reduction method according 
to Navarro-Gonzalez et al. [14], based on the 
Griess-reaction. Moderately elevated albuminuria 
(formerly known as microalbuminuria) is defined 
as a urinary albumin-creatinine ratio (UACR) in the 
range from 3.4 mg/mmol to 34 mg/mmol [15]. The 
UACR was measured on the third day after admis-
sion to hospital in the first morning urine sample. 
The use of the initial morning urine specimen was 
recommended because, at that time, the influence 
of food intake and water, as well as physical activity 
on albuminuria is the weakest. Albumin in the urine 
was determined by a photometric color test with 
pyrogallol red on the Olympus AU 400 analyzer 
(Olympus, Tokyo, Japan). 
An echocardiography examination was per-
formed 24 h after admission to hospital. At hospital 
discharge and at the last clinical ambulatory control 
after 24 months, the Sexual Health Inventory for 
Men (SHIM), the Serbian version of the assess-
ment of the existence of ED in the last 6 months, 
validated by the World Health Organization, was 
used as an assessment [16]. The questionnaire 
consisted of 5 questions and each question were 
scored on a 5-point ordinal scale in which lower 
values represent poorer sexual function. The 
response 0 for a question is considered the least 
functional, while the response 5 was considered 
the most functional. The possible scores for the 
questionnaire range from 1 to 25 (each question 
has a score of 1–5), and a score above 21 was 
considered as normal erectile function and at or 
below this cut-off point as ED. According to this 
scale, ED is classified into four categories based 
on the total score: severe (1–7), moderate (8–11), 
mild to moderate (12–16), mild (17–21), and no 
ED (22–25) [17].
Statistical analysis
All statistical calculations were performed us-
ing appropriate (non)parametric tests after verifica-
tion of the distribution of the values in each group. 
All comparisons between (sub)groups were per-
formed using the Mann-Whitney test, or ANOVA 
when appropriate. Spearman’s rank correlation 
coefficient and the Pearson bivariate correlation 
analysis were used to investigate the relationship 
between two comparable variables; also, linear 
regression analysis was used to verify the level of 
the relationship examined. The biomarkers exam-
ined, together with the major risk factors for CVD, 
were included in the logistic regression analysis. To 
assess the ability of NO to predict ED incidence/ 
/prevalence, receiver-operator characteristic (ROC) 
curves were given with the area calculated under 
the curve (AUC), i.e. c-statistic. All data are pre-
sented as medians with the interquartile ranges, 
or when it was appropriate as means ± standard 
deviation. P < 0.05 was considered as significant. 
All statistical calculations were done using SPSS 
17.0 for Windows (SPSS Inc., USA).
Results
The study included 61 men with a MI with ST-
-segment elevation (STEMI), 34.4% of whom had 
ED. Nineteen men had a MI without ST segment 
elevation (NSTEMI), among whom, 57.9% had ED 
which had lasted at least 6 months before AMI. 
Thus, 32 (40.1%) of the men with AMI had some 
degree of ED. There was no significant difference 
in the prevalence of ED among the patients with 
NSTEMI or STEMI. 
A significant difference between the severity 
of ED at initial hospitalization and after 2 years 
was found. The percentage of patients without ED 
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increased, while the percentage of patients with 
severe ED significantly decreased after 2 years 
(Table 1). There was no significant difference in 
the prevalence of CV risk factors or in the preva-
lence of previously diagnosed CVD among patients 
with/without ED assessed at hospital admission 
(Table 2). 
The clinical and biochemical characteristics 
of patients with/without ED at admission are pre-
sented in Table 3. No significant difference was 
found between the parameters in patients with/
without ED.
Among the clinical and biochemical param-
eters tested, we only found a significant difference 
in NO and BNP concentrations between patients 
without ED and those with severe ED (Table 4). 
The levels of BNP and NO, measured 72 h 
after AMI were significantly different between 
patients with and without ED at hospital admission 
and between those with or without ED 2 years 
after AMI. An insignificantly higher percentage of 
patients with ED (during initial hospitalization and 
after the 2-year follow-up) had proteinuria (micro- 
or macroalbuminuria) (Table 4).
The age of the patient, left ventricular ejec-
tion fraction (LVEF), reduced LVEF (below 45%) 
and low levels of NO in the univariate model were 
associated with a higher risk of ED (Table 5). The 
multivariate model found NO, age and LVEF less 
than 45% to be independent predictors for ED. The 
use of NO donors, angiotensin converting enzyme 
(ACE) inhibitors/AT1 blockers, beta-blockers, 
statins and diuretics was not associated with higher 
risk of ED in the logistic regression analysis. In 
the ROC analysis it was revealed that concen-
trations of NO < 139.3 mmol/L (AUC = 0.676, 
95% CI 0562–0677, p = 0.003) had a sensitivity of 
75.0% and a specificity of 58.3% for the diagnosis 
of ED at hospital admission (Fig. 1). In the uni-
variate model, it was found that with age, longer 
duration of hypertension, elevated BNP and fibrino-
gen concentrations, reduced NO levels, and with 
re-hospitalizations during the 2-year follow up, 
the probability of the existence/occurrence of 
Table 1. Presence and severity of erectile dysfunction (ED) in acute myocardial infarction (AMI) and 
after 2 years of follow-up.
Severity of ED At hospitalization 2-years after AMI c2 test/p
0 (without ED) 48 (60%) 52 (73.2%) NS
1 (mild) 15 (18.8%) 9 (12.7%) NS
2 (mild to moderate) 3 (3.8%) 5 (7%) NS
3 (moderate) – 3 (4.2%) –
4 (severe) 14 (17.5%) 2 (2.8%) c2 = 7.103, p < 0.01
Total 80 (100%) 71 (100%)
Table 2. Previous cardiovascular diseases and risk factors at admission in patients with and without 
erectile dysfunction (ED).
Patients with ED  
at hospital admission
Patients without ED  
at hospital admission 
Arterial hypertension 24 (75%) 36 (75%)
Angina pectoris 16 (50%) 18 (37.5%)
Previous myocardial infarction 9 (28.1%) 10 (20.8%)
Coronary artery bypass grafting 2 (6.3%) 1 (2.1%)
CVI/TIA 2 (6.3%) 3 (6.3%)
Newly diagnosed diabetes mellitus 4 (12.5%) 2 (4.2%)
Nonsmokers 6 (18.8%) 10 (20.8%)
Smokers 14 (43.8%) 26 (54.2%)
Ex-smokers 12 (37.5%) 12 (25%)
Dyslipidemia 10 (31.3%) 23 (47.9%)
CVI — cerebrovascular insult/stroke; TIA — transient ischemic attack
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Table 3. Clinical characteristics and biochemical parameters in patients at hospital admission.
Clinical characteristic/ 
/biochemical  
parameter at hospital 
admission
Degree of ED assessed at hospital admission
0  
(without ED)
1  
(mild ED)
2 (mild to  
moderate ED)
4  
(severe ED)
Age [years] 59.9 ± 10.03 64.2 ± 8.25 70.33 ± 11.59 66.5 ± 12.18
Systolic BP [mm Hg] 132.23 ± 26.14 133.33 ± 26.43 143.33 ± 20.81 137.79 ± 33.08
Diastolic BP [mm Hg] 82.87 ± 16.77 82.00 ± 13.20 83.33 ± 15.27 85.14 ± 19.06
BMI [kg/m2] 27.72 ± 3.80 27.70 ± 4.75 27.89 ± 1.43 26.09 ± 3.43
LVEF [%] 53.67 ± 7.8 49.53 ± 12.92 52.0 ± 8.54 45.85 ± 13.85
LVEF > 45% 91.3% 53.3% 33.3% 38.5%
Duration of AH [years] 8.41 ± 6.9 8.1 ± 6.45 13.3 ± 7.6 11.6 ± 9.7
BNP [pg/mL] 245.90 (191.30– 
–400.60)* 
409.00 (366.50– 
–455.30)
698.60 (387.40– 
–1070.00)
2781.45 (562.90– 
–5000.00)**
ET-1 [pg/mL] 2.86 (2.44–4.19) 3.07 (2.95–3.58) 3.68 (2.35–3.89) 8.47 (3.04–13.91)
NO [µmol/L] 155.20 (140.50– 
–177.40)* 
128.60 (123.60– 
–167.40)
122.4  
(110.3–148.1)
143.65 (102.40– 
–184.90)**
hsTnI [ng/mL] 30.58 ± 53.79 31.14 ± 39.9 7.48 ± 10.87 51.42 ± 11.13
hsCRP [mg/L] 22.07 ± 34.32 22.38 ± 39.25 45.22 ± 38.77 34.39 ± 45.59
Fibrinogen [g/L] 5.94 ± 1.71 5.93 ± 1.43 6.7 ± 4.66 6.49 ± 2.23
UACR [mg/mmol] 3.39 ± 6.67 3.38 ± 5.56 0.66 ± 0.41 8.42 ± 21.99
Cholesterol [mmol/L] 5.29 ± 1.36 5.31 ± 1.56 5.97 ± 0.49 5.30 ± 1.23
LDL [mmol/L] 3.58 ± 1.01 3.93 ± 1.23 3.90 ± 0.98 3.36 ± 1.16
HDL [mmol/L] 1.19 ± 0.20 0.99 ± 0.18 1.37 ± 0.31 1.25 ± 0.27
Triglycerides [mmol/L] 1.62 ± 0.90 1.54 ± 0.54 1.49 ± 0.29 1.50 ± 0.87
*vs. **: p < 0.05; AH — arterial hypertension; BMI — body mass index;  BNP — B-type natriuretic peptide; BP — blood pressure; ED — erec-
tile dysfunction; ET-1 — endothelin-1; HDL — high density lipoprotein; hsCRP — high sensitivity C-reactive protein; hsTnI — high sensitivity 
troponin I; LDL — low density lipoprotein; LVEF — left ventricular ejection fraction; NO — nitric oxide degradation products; UACR — urinary 
albumin-creatinine ratio
Table 4. Biomarkers in patients with/without erectile dysfunction (ED) at hospital admission and after  
2 years.
Biomarkers Patients with vs. without ED  
during the initial hospitalization 
Patients with vs. without ED  
2 years after AMI
Albuminuria 24 (30%) vs. 21 (26.8%) 26 (37.5%) vs. 15 (21.7%) 
BNP [pg/mL] 455.30 (387.75–630.75)* vs.  
236.10 (162.60–400.60)**
562.90 (387.75–750.55)* vs.  
236.10 (162.60–400.60)**
NO [µmol/L] 128.60 (115.50–149.60)* vs.  
156.80 (141.10–179.30)**
131.80 (115.50–160.50* vs.  
156.80 (140.50–181.80)**
*vs. **: p < 0.05; AMI — acute myocardial infarction; BNP — B-type natriuretic peptide; NO — nitric oxide degradation products
Table 5. Logistic regression analysis for diagnosis of erectile dysfunction at hospital admission.
Parameter Univariate analysis Multivariate analysis
OR 95% CI P OR 95% CI P
Nitric oxide degradation products 0.978 0.96120.995 0.010 0.976 0.956–0.995 0.016
LVEF 0.948 0.904–0.994 0.047
LVEF category (< or ≥ 45%) 0.132 0.038–0.460 0.001 5.579 1.502–21.476 0.010
Age 1.060 1.011–1.112 0.016 1.057 1.002–1.117 0.049
CI — confidence interval; LVEF — left ventricular ejection fraction; OR — odds ratio
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ED 2 years after the AMI had increased. In the 
multivariate model, increased age and decreased 
NO levels measured at hospital admission were 
independent predictors for the presence of ED 
2 years after the AMI in our patients (Table 6). Using 
ROC analysis, we found that admission levels of 
NO < 134.9 (AUC = 0.658, 95% CI 0536–0767, 
p = 0.02) had a sensitivity of 73.68% and specificity 
of 55.77% for the ED diagnosis 2 years after MI 
(Fig. 2).
During the 2-years of follow-up, 9 patients died 
(6.5% without ED, 6.7% with mild ED, 33.3% with 
moderate to severe and 28.6% patients with severe 
ED) (c2 = 7.19, p = 0.015). During the same time 
period, 22 (27.5%) patients were re-hospitalized 
due to CV causes, of whom 59.1% had ED at hos-
pital admission (p < 0.05).
After hospital discharge, 52.5% of these pa-
tients had NO donors in therapy (long-acting 
nitrates and molsidomine). 59.4% of the patients 
with ED and 47.9% of those without ED (p = NS) 
had NO donors in therapy. After 2 years, 52.6% of 
the patients with ED and 51.9% of those without 
ED (p = NS) had NO donors in therapy. Patients 
Figure 1. Receiver-operator characteristic (ROC) curve 
for nitric-oxide degradation products in predicting erec-
tile dysfunction in patients with acute myocardial dys-
function.
Figure 2. Receiver-operator characteristic (ROC) curve 
for nitric-oxide degradation products in predicting erec-
tile dysfunction two years after myocardial infarction.
Table 6. Logistic regression analysis of the risk factors for erectile dysfunction 2 years after acute  
myocardial infarction.
Parameter Univariate analysis Multivariate analysis
OR 95% CI P OR 95% CI P
Re-hospitalization 0.202 0.062–0.654 0.008
Age 1.111 1.040–1.187 0.002 1.126 1.047–1.211 0.001
B-type natriuretic peptide 1.005 1.001–1.010 0.010
Fibrinogen 1.452 1.021–2.066 0.038
Nitric oxide degradation products 0.978 0.958–0.998 0.039 0.973 0.951–0.997 0.025
Duration of arterial hypertension 1.090 1.006–1.188 0.049
CI — confidence interval; OR — odds ratio
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with improved sexual function (ED at admission 
and with normal sexual function after 2 years — 
15.7%), more frequently had NO donors in therapy 
(81.8% vs. 45.8%, p = 0.046), as opposed to those 
without changes in erectile functioning. There was 
no significant difference among patients without 
ED compared to those with ED in the frequency 
of the use of beta-blockers (79.2% vs. 81.3%), 
ACE inhibitors/AT1 blockers (81.3% vs. 81.3%), 
statins (93.8% vs. 93.8%) or diuretics (18.8% vs. 
34.4%) at hospital discharge. None of our patients 
used type V phosphodiesterase (PDE) inhibitors 
during the 2 years.
Discussion
Forty percent of the patients with AMI had ED 
at hospital admission. After 2 years the number of 
patients with ED had significantly decreased (to 
26.5%), and the percentage of patients with severe 
ED was significantly reduced (from 17.5% to 2.8%). 
This may also be the consequence of lifestyle 
changes and the use of medications.
Erectile dysfunction is now considered pri-
marily as a vascular disease that shares the same 
risk factors as CAD [18]. ED and CVD are two 
different manifestations of the same systemic 
disturbance. The relationship between these 
pathological conditions lies in the interaction 
between CV risk factors, androgens, and chronic 
inflammation, which leads to arteriosclerosis 
and stenosis, which reduces arterial blood flow. 
Macroscopic non-visible changes, such as endo-
thelial dysfunction or autonomic hyper-reactivity, 
may partially explain the complex relationship 
between ED and CVD. ED usually precedes 
CAD and its diagnosis provides an opportunity 
for risk assessment and the prevention of CHD. 
Also, prevention of CAD has a beneficial effect 
on erectile function [2, 3]. In the COBRA trial it 
was shown that in patients with chronic coronary 
disease with diffuse atherosclerosis, the ED is 
more severe than in those with the single vessel 
disease and acute coronary syndrome. Therefore, 
in patients with a higher atherosclerotic burden 
and more extensive endothelial dysfunction the 
ED is more severe [19]. 
A significant correlation was found between 
ED and the number of occluded coronary arteries 
during angiography. Also, in 16% of cases, patients 
with severe vascular ED (revealed by duplex 
sonography) had a severe or asymptomatic form 
of ischemic heart disease. Changes in the endo-
thelial L-arginine-NO pathway are shown in the 
atherosclerotic coronary arteries and in penile and 
pelvic arteries in patients with ED. These studies 
support the concept of a reduction in the bioavail-
ability of NO as an underlying cause of CVD and 
ED. Accordingly, vascular changes in the blood flow 
through the penis are a mirror of those that exist 
in the coronary blood vessels [18].
Patients with and without ED at hospital ad-
mission had no significant differences in the preva-
lence of CV risk factors or CVD. It is possible that 
testosterone deficiency in this group of patients had 
greater significance in the pathogenesis of ED than 
atherosclerosis and endothelial dysfunction [20]. 
Presumably, the treatment of patients with CVD 
or the risk factors could have had an influence on 
erectile function. There was no significant differ-
ence between the number of patients treated with 
NO donors, with and without ED, at the beginning 
or at the end of this study. Patients with improved 
sexual function more frequently had 
Nitric oxide donors in therapy, which is not 
in line with previous studies. Burnett et al. [21] 
demonstrated that transdermal administration 
of nitroglycerin using a patch or plaster had only 
moderate and inconsistent efficacy in improving 
erectile function. It is possible that other drugs 
(ACE inhibitors or angiotensin [AT1] receptor 
antagonists, beta-blockers — nebivolol, antiag-
gregation therapy, statins) and physical activity 
with the adoption of a new, healthy lifestyle (quit-
ting smoking and/or losing weight) also had an 
impact on improving erectile function after AMI. 
Depression is common in patients with AMI and 
ED. It is possible that lifestyle modifications after 
AMI improve the symptoms of depression and thus 
indirectly improve erectile functioning. Lemogne 
et al. [22] showed that in contrast to drugs, depres-
sive mood is a better predictor for ED in logistic 
regression analysis.
There was a significant difference between the 
concentrations of NO and BNP measured at hospi-
tal admission in patients with/without ED during 
initial hospitalization and 2 years after the initial 
event. Patients with ED during AMI had elevated 
BNP levels and reduced NO values compared to 
those without ED. This finding supports the fact 
that left ventricular hemodynamic overload and 
consequent neurohumoral activation lead to the 
decreased bioavailability of NO in more severe 
forms of atherosclerosis, where penile arteries 
are also affected [23]. Oxidative stress is a key 
pathogenic factor in vascular diseases, such as 
hypertension and atherosclerosis, and it is found 
to be increased in ED [9]. Therefore in conditions 
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with increased oxidative stress, NO is involved in 
nitrosative stress. 
A similar percentage of patients with ED dur-
ing the initial event, and then after 2 years, had 
micro- or macroalbuminuria. This is not in line with 
previous studies in which albuminuria was found to 
be an indicator of systemic vascular permeability. 
Albuminuria in hypertensive patients, even below 
the lower referent value, is considered to be 
a significant predictor of CV events. A study with 
diabetic patients with ED and with angiographically 
proven coronary disease, in whom hypertension 
was very common, showed a significant association 
between microalbuminuria and CV events [23]. 
Microalbuminuria is a predictor of short and long 
term prognosis in AMI [12, 24]. 
In logistic regression analysis, as independent 
factors associated with an increased risk of ED we 
found NO below 139.3 mmol/L, the LVEF below 
45% and older age. Independent predictors for ED, 
2 years after the initial event, were older in age 
and had lower NO levels. The LVEF did not keep 
its independence as a predictor, which could be the 
consequence of an improved functional and pos-
sibly hormonal status after 2 years and the use of 
medications (beta-blockers, ACE inhibitors, statins 
and others). In fact, prior to the initial event a large 
percentage of patients had CVD or risk factors for 
it. We assume that after AMI patients carefully 
adhered to the recommendations involving life-
style changes and regular use of therapy. In the 
univariate model, the risk of the existence of ED 
after 2 years was increased by re-hospitalizations 
during the follow-up period, a longer duration of 
hypertension, higher levels of BNP and fibrino-
gen. In patients who were re-hospitalized during 
the follow-up period, beside atherosclerosis, psy-
chological factors could have had an effect on the 
impaired ED.
Aging, health status and gender affect sexual 
function. In population studies, men are more often 
sexually active and satisfied with a good sexual 
life than women [25]. Gender differences increase 
with age and are most prominent in the period from 
75 to 85 years of age: approximately 39% of men 
vs. 17% of women are sexually active. Men and 
women with good health status are more sexually 
active than those with health problems. Although 
men remain sexually active, many of the changes 
associated with aging occur in sexual functioning, 
including delayed erection, decreased intensity 
and duration of orgasm, and ejaculation disorders 
[26]. All of these factors could have affected our 
study group.
Nitric oxide plays a major role in the physiol-
ogy of penile erection. NO achieves these effects 
through the activation of guanylate cyclase and the 
subsequent production of cGMP. Reduction in the 
bioavailability of NO plays an important role in the 
pathogenesis of ED [18]. Accordingly we found that 
patients with more severe forms of ED had higher 
levels of NO degradation products, and presumably 
less available concentrations of NO. This “damaged 
activity of NO” could be similar to that found in other 
forms of vascular diseases in the presence of CV 
risk factors (e.g., smoking, dyslipidemia, diabetes, 
and hypertension) when the down-regulation of en-
dothelial NO synthase is present. The development 
of type V PDE inhibitors that inhibit the breakdown 
of GMP has been revolutionary in the treatment of 
ED [18].
Although it would be expected that ET-1, as 
a strong vasoconstrictor, has an influence on the 
progression of ED, our results do not support pre-
vious research. ET-1 is also a significant inducer 
of oxidative stress, and experiments show that it 
can contribute to endothelial dysfunction in the 
penile arteries in states of insulin resistance. This 
confirms the key role of NADPH oxidase in vas-
cular reactive oxygen species production in obese 
patients with insulin resistance. It has been shown 
that ET-B receptor antagonism reduces oxidative 
stress and endothelial dysfunction caused by ET-1 
in the erectile tissue in obese patients with insulin 
resistance. The results of these studies suggest 
that the antagonism of ET-B receptors may be 
useful in the endothelial dysfunction associated 
with insulin ED-resistant conditions [9].
There is an ongoing debate regarding the use 
of ED as a risk factor in the primary and secondary 
risk assessment of CAD. Younger patients with 
ED and a moderate to severe CV risk are recom-
mended taking further diagnostic procedures for 
detecting CAD. Besides biomarkers such as hsCRP, 
the glycosylated hemoglobin test (HbA1c), urinary 
albumin excretion, and lipoprotein-associated phos-
pholipase A2, the procedures include non-invasive 
and invasive imaging. A positive stress test for 
inducible ischemia correlates with the presence of 
ED and with a decreased mean cavernous artery 
peak systolic velocity (< 35 cm/s). Also, increased 
carotid intima–media thickness and an increased 
coronary artery calcium score, quantified using 
non-contrast computerized tomography or elec-
tron beam scan, correlate with the presence of 
ED. It was shown that multi-detector computed 
tomography–coronary angiography (MDCT-CA) 
can better detect “silent” coronary artery plaques 
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in men with ED and lack of evidence for CAD than 
when detected with stress electrocardiogram [27]. 
This measurement of biomarkers is less expensive, 
less time-consuming, more available and easier to 
perform than imaging procedures in patients with 
ED. The “ideal” combination of biomarkers for 
risk stratification in patients with CV risk and ED 
remain to be determined.
Limitations of the study
Some study limitations need to be addressed. 
The major limitation is a relatively small sample 
size. Also, we did not have the serial measure-
ments of the markers of endothelial dysfunction, 
oxidative stress and inflammation. The testoster-
one concentrations were not measured since it is 
not a routine marker measured during AMI. Its 
concentration decreases in AMI, and it was also 
expected in older patients, in agreement with this 
study. Further, the study design did not predict 
repeating measurements of the biomarkers.  
Conclusions
Erectile dysfunction, alone, was a marker for 
poor prognosis after MI. Patients with ED prior to 
the AMI were at increased risk of 2-year mortality 
and re-hospitalization due to CVD. Older age and 
decreased NO concentration, measured on the third 
day after AMI, were independent predictors of ED 
prevalence and incidence even 2 years after AMI. 
Treatment of ED could improve the prognosis after 
AMI, principally by increasing the NO bioavailabil-
ity and  improvement in the quality of life.
Acknowledgements
The authors want to thank Prof. Vidosava 
Djordjevic, Prof. Vladan Cosic, Prof. Ivana Sto-
janovic and Dr Tatjana Ristic from the Central 
Laboratory at Nis Clinical Center and the Medical 
Faculty at the University of Nis, for performing 
the biochemical analyses and for their valuable 
suggestions.
Conflict of interest: None declared
References
1. Ritchie R, Sullivan M. Endothelins & erectile dysfunction. Phar-
macol Res. 2011; 63(6): 496–501, doi: 10.1016/j.phrs.2010.12.006, 
indexed in Pubmed: 21185376.
2. Vlachopoulos C, Jackson G, Stefanadis C, et al. Erectile dysfunc-
tion in the cardiovascular patient. Eur Heart J. 2013; 34(27): 
2034–2046, doi: 10.1093/eurheartj/eht112, indexed in Pub-
med: 23616415.
3. Gandaglia G, Briganti A, Jackson G, et al. A systematic review 
of the association between erectile dysfunction and cardiovas-
cular disease. Eur Urol. 2014; 65(5): 968–978, doi:  10.1016/j.
eururo.2013.08.023, indexed in Pubmed: 24011423.
4. Guo W, Liao C, Zou Y, et al. Erectile dysfunction and risk of 
clinical cardiovascular events: a meta-analysis of seven cohort 
studies. J Sex Med. 2010; 7(8): 2805–2816, doi: 10.1111/j.1743-
6109.2010.01792.x, indexed in Pubmed: 20367771.
5. Dong JY, Zhang YH, Qin LQ. Erectile dysfunction and risk of 
cardiovascular disease: meta-analysis of prospective cohort stud-
ies. J Am Coll Cardiol. 2011; 58(13): 1378–1385, doi: 10.1016/j.
jacc.2011.06.024, indexed in Pubmed: 21920268.
6. Vlachopoulos CV, Terentes-Printzios DG, Ioakeimidis NK, et 
al. Prediction of cardiovascular events and all-cause mortality 
with erectile dysfunction: a systematic review and meta-analysis 
of cohort studies. Circ Cardiovasc Qual Outcomes. 2013; 6(1): 
99–109, doi: 10.1161/CIRCOUTCOMES.112.966903, indexed in 
Pubmed: 23300267.
7. Szymański FM, Filipiak KJ, Płatek AE, et al. Can thromboem-
bolic risk be associated with erectile dysfunction in atrial fibril-
lation patients? Cardiol J. 2015; 22(4): 446–452, doi:  10.5603/
CJ.a2015.0010, indexed in Pubmed: 25733318.
8. Brown RA, Lip GYH. Erectile dysfunction in atrial fibrillation: 
a risk factor for stroke or a reflection of stroke risk factors? Cardiol J. 
2015; 22(4): 359–361, doi:  10.5603/CJ.2015.0049, indexed in 
Pubmed: 26315023.
9. Sánchez A, Martínez P, Muñoz M, et al. Endothelin-1 contrib-
utes to endothelial dysfunction and enhanced vasoconstriction 
through augmented superoxide production in penile arteries 
from insulin-resistant obese rats: role of ET(A) and ET(B) recep-
tors. Br J Pharmacol. 2014; 171(24): 5682–5695, doi: 10.1111/
bph.12870, indexed in Pubmed: 25091502.
10. LoPresti R, Catania A, D’Amico T, et al. Oxidative stress in 
young subjects with acute myocardial infarction: evaluation at 
the initial stage and after 12 months. Clin Appl Thromb Hemost. 
2008; 14(4): 421–427, doi: 10.1177/1076029607308406, indexed 
in Pubmed: 18160607.
11. Omland T, Lie RT, Aakvaag A, et al. Plasma endothelin determi-
nation as a prognostic indicator of 1-year mortality after acute 
myocardial infarction. Circulation. 1994; 89(4): 1573–1579, in-
dexed in Pubmed: 8149523.
12. Apostolovic S, Stanojevic D, Djordjevic V, et al. Prognostic sig-
nificance of microalbuminuria in patients with acute myocardial 
infarction. Clin Lab. 2011; 57(3-4): 229–235, indexed in Pub-
med: 21500732.
13. Thygesen K, Alpert JS, Jaffe AS, et al. Writing Group on the Joint 
ESC/ACCF/AHA/WHF Task Force for the Universal Definition 
of Myocardial Infarction, ESC Committee for Practice Guidelines 
(CPG). Third universal definition of myocardial infarction. Eur 
Heart J. 2012; 33(20): 2551–2567, doi: 10.1093/eurheartj/ehs184, 
indexed in Pubmed: 22922414.
14. Navarro-Gonzálvez JA, García-Benayas C, Arenas J. Semiauto-
mated measurement of nitrate in biological fluids. Clin Chem. 
1998; 44(3): 679–681, indexed in Pubmed: 9510886.
15. K/DOQI clinical practice guidelines and clinical practice recom-
mendations for diabetes and chronic kidney disease. Am J Kidney 
Dis, 2007; 49 (2 Suppl. 2): S12/154.
16. Rosen RC, Cappelleri JC, Smith MD, et al. Development and 
evaluation of an abridged, 5-item version of the International In-
dex of Erectile Function (IIEF-5) as a diagnostic tool for erectile 
dysfunction. Int J Impot Res. 1999; 11(6): 319–326, indexed in 
Pubmed: 10637462.
www.cardiologyjournal.org 401
Svetlana Apostolovic et al., Erectile dysfunction in acute myocardial infarction
17. Rhoden EL, Telöken C, Sogari PR, et al. The use of the simplified 
International Index of Erectile Function (IIEF-5) as a diagnostic 
tool to study the prevalence of erectile dysfunction. Int J Impot 
Res. 2002; 14(4): 245–250, doi: 10.1038/sj.ijir.3900859, indexed 
in Pubmed: 12152112.
18. Sullivan ME, Thompson CS, Dashwood MR, et al. Nitric oxide 
and penile erection: is erectile dysfunction another manifesta-
tion of vascular disease? Cardiovasc Res. 1999; 43(3): 658–665, 
indexed in Pubmed: 10690337.
19. Montorsi P, Ravagnani PM, Galli S, et al. Association between 
erectile dysfunction and coronary artery disease. Role of coro-
nary clinical presentation and extent of coronary vessels involve-
ment: the COBRA trial. Eur Heart J. 2006; 27(22): 2632–2639, 
doi: 10.1093/eurheartj/ehl142, indexed in Pubmed: 16854949.
20. Schwarz ER, Rastogi S, Rodriguez JJ, et al. A multidisciplinary 
approach to assess erectile dysfunction in high-risk cardiovas-
cular patients. Int J Impot Res. 2005; 17 Suppl 1: S37–S43, 
doi: 10.1038/sj.ijir.3901427, indexed in Pubmed: 16391541.
21. Burnett AL. The role of nitric oxide in erectile dysfunction: 
implications for medical therapy. J Clin Hypertens (Greenwich). 
2006; 8(12 Suppl 4): 53–62, indexed in Pubmed: 17170606.
22. Lemogne C, Ledru F, Bonierbale M, et al. Erectile dysfunction 
and depressive mood in men with coronary heart disease. Int 
J Cardiol. 2010; 138(3): 277–280, doi: 10.1016/j.ijcard.2008.08.017, 
indexed in Pubmed: 18789827.
23. Vlachopoulos C, Ioakeimidis N, Stefanadis C. Biomarkers, erec-
tile dysfunction, and cardiovascular risk prediction: the latest 
of an evolving concept. Asian J Androl. 2015; 17(1): 17–20, 
doi: 10.4103/1008-682X.143250, indexed in Pubmed: 25412676.
24. Lekatsas I, Koulouris S, Triantafyllou K, et al. Prognostic 
significance of microalbuminuria in non-diabetic patients 
with acute myocardial infarction. Int J Cardiol. 2006; 106(2): 218–223, 
doi: 10.1016/j.ijcard.2005.02.004, indexed in Pubmed: 16321695.
25. Lindau ST, Gavrilova N. Sex, health, and years of sexually active 
life gained due to good health: evidence from two US population 
based cross sectional surveys of ageing. BMJ. 2010; 340: c810, 
indexed in Pubmed: 20215365.
26. Kandeel FR, Koussa VK, Swerdloff RS. Male sexual function and 
its disorders: physiology, pathophysiology, clinical investigation, 
and treatment. Endocr Rev. 2001; 22(3): 342–388, doi: 10.1210/
edrv.22.3.0430, indexed in Pubmed: 11399748.
27. Raheem OA, Su JJ, Wilson JR, et al. The Association of Erec-
tile Dysfunction and Cardiovascular Disease: A Systematic 
Critical Review. Am J Mens Health. 2016 [Epub ahead of 
print], doi:  10.1177/1557988316630305, indexed in Pubmed:   
26846406.
402 www.cardiologyjournal.org
Cardiology Journal 2017, Vol. 24, No. 4
